2. Academic Validation
  3. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice

Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice

  • Cardiovasc Res. 2016 Jun 1;110(3):319-30. doi: 10.1093/cvr/cvw054.
Jason M Aliotta 1,  Mandy Pereira 2,  Sicheng Wen 2,  Mark S Dooner 2,  Michael Del Tatto 2,  Elaine Papa 2,  Laura R Goldberg 2,  Grayson L Baird 3,  Corey E Ventetuolo 4,  Peter J Quesenberry 2,  James R Klinger 4
Affiliations

Affiliations

  • 1 Department of Medicine, Division of Hematology/Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI 02903, USA jason_aliotta@brown.edu jaliotta@lifespan.org.
  • 2 Department of Medicine, Division of Hematology/Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA.
  • 3 Lifespan Biostatistics Core, Rhode Island Hospital, Providence, RI 02903, USA.
  • 4 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI 02903, USA.
PMID: 26980205 DOI: 10.1093/cvr/cvw054
Abstract

Aims: Extracellular vesicles (EVs) from mice with monocrotaline (MCT)-induced pulmonary hypertension (PH) induce PH in healthy mice, and the exosomes (EXO) fraction of EVs from mesenchymal stem cells (MSCs) can blunt the development of hypoxic PH. We sought to determine whether the EXO fraction of EVs is responsible for modulating pulmonary vascular responses and whether differences in EXO-miR content explains the differential effects of EXOs from MSCs and mice with MCT-PH.

Methods and results: Plasma, lung EVs from MCT-PH, and control mice were divided into EXO (exosome), microvesicle (MV) fractions and injected into healthy mice. EVs from MSCs were divided into EXO, MV fractions and injected into MCT-treated mice. PH was assessed by right ventricle-to-left ventricle + septum (RV/LV + S) ratio and pulmonary arterial wall thickness-to-diameter (WT/D) ratio. miR microarray analyses were also performed on all EXO populations. EXOs but not MVs from MCT-injured mice increased RV/LV + S, WT/D ratios in healthy mice. MSC-EXOs prevented any increase in RV/LV + S, WT/D ratios when given at the time of MCT injection and reversed the increase in these ratios when given after MCT administration. EXOs from MCT-injured mice and patients with idiopathic pulmonary arterial hypertension (IPAH) contained increased levels of miRs-19b,-20a,-20b, and -145, whereas miRs isolated from MSC-EXOs had increased levels of anti-inflammatory, anti-proliferative miRs including miRs-34a,-122,-124, and -127.

Conclusion: These findings suggest that circulating or MSC-EXOs may modulate pulmonary hypertensive effects based on their miR cargo. The ability of MSC-EXOs to reverse MCT-PH offers a promising potential target for new PAH therapies.

Keywords

Exosomes; Extracellular vesicles; Mesenchymal stem cells; MicroRNA; Pulmonary hypertension.

Figures
Products